X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2136) 2136
Publication (223) 223
Newsletter (53) 53
Book Review (38) 38
Book Chapter (4) 4
Newspaper Article (4) 4
Transcript (2) 2
Data Set (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
adefovir dipivoxil (1790) 1790
humans (1435) 1435
lamivudine (975) 975
antiviral agents - therapeutic use (917) 917
index medicus (911) 911
hepatitis b (897) 897
hepatitis b, chronic - drug therapy (897) 897
gastroenterology & hepatology (843) 843
male (672) 672
adenine - analogs & derivatives (618) 618
female (605) 605
adult (587) 587
hepatitis b virus (541) 541
middle aged (534) 534
hepatitis b virus - genetics (478) 478
treatment outcome (471) 471
hepatitis b virus - drug effects (468) 468
therapy (455) 455
entecavir (450) 450
lamivudine - therapeutic use (433) 433
adenine - therapeutic use (424) 424
pharmacology & pharmacy (380) 380
organophosphonates - therapeutic use (369) 369
tenofovir (352) 352
chronic hepatitis b (341) 341
virology (335) 335
hepatitis b, chronic - virology (333) 333
hepatitis (326) 326
drug resistance, viral (310) 310
hepatocellular-carcinoma (309) 309
drug therapy, combination (305) 305
adefovir (301) 301
dna, viral - blood (290) 290
antiviral agents (283) 283
infectious diseases (283) 283
infection (280) 280
mutation (268) 268
guanine - analogs & derivatives (264) 264
resistance (251) 251
tenofovir disoproxil fumarate (248) 248
drug therapy (246) 246
interferon (246) 246
antiviral agents - pharmacology (245) 245
drug resistance (235) 235
hepatitis b - drug therapy (233) 233
antiviral agents - administration & dosage (230) 230
hepatitis b e antigens - blood (228) 228
health aspects (225) 225
viral load (221) 221
aged (217) 217
lamivudine therapy (217) 217
virus-infection (214) 214
care and treatment (213) 213
antiviral agents - adverse effects (206) 206
efficacy (206) 206
hbv (201) 201
dipivoxil (198) 198
telbivudine (196) 196
guanine - therapeutic use (194) 194
virus diseases (193) 193
e-antigen (190) 190
lamivudine treatment (183) 183
virus (183) 183
antiviral therapy (180) 180
dna (179) 179
combination (177) 177
natural-history (173) 173
liver (170) 170
genotype (164) 164
time factors (162) 162
peginterferon alpha-2a (161) 161
cirrhosis (160) 160
reverse transcriptase inhibitors - therapeutic use (157) 157
in-vitro (156) 156
liver transplantation (156) 156
mutations (154) 154
management (153) 153
adenine - administration & dosage (149) 149
research (149) 149
analysis (148) 148
combination therapy (148) 148
drug resistance, viral - genetics (147) 147
transplantation (140) 140
digestive system diseases (139) 139
chronic hepatitis-b (138) 138
hepatitis b, chronic - complications (138) 138
organophosphonates - administration & dosage (134) 134
risk factors (134) 134
safety (134) 134
virus infection (134) 134
gastroenterology and hepatology (129) 129
hepatitis b, chronic - diagnosis (129) 129
retrospective studies (129) 129
interferon-alpha - therapeutic use (127) 127
deoxyribonucleic acid--dna (126) 126
hepatitis b, chronic - blood (126) 126
adefovir dipivoxil therapy (125) 125
adenine - adverse effects (125) 125
alanine transaminase - blood (124) 124
replication (124) 124
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2043) 2043
French (48) 48
Korean (35) 35
Chinese (16) 16
Spanish (15) 15
German (14) 14
Japanese (11) 11
Portuguese (7) 7
Czech (6) 6
Polish (2) 2
Turkish (2) 2
Hungarian (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Hepatology, ISSN 0168-8278, 07/2019, Volume 71, Issue 1, pp. 35 - 44
Tenofovir disoproxil fumarate (TDF) monotherapy has displayed non-inferior efficacy to TDF plus entecavir (ETV) combination therapy in patients with hepatitis... 
Resistance | Adefovir dipivoxil | Lamivudine | Hepatitis B virus | HBV | Entecavir | EFFICACY | EMTRICITABINE | RISK | DIPIVOXIL | FAILURE | HEPATOCELLULAR-CARCINOMA | ALAFENAMIDE | VIRUS INFECTION | ANALOG THERAPY | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2011, Volume 364, Issue 4, pp. 322 - 331
Journal Article
Journal of Acute Disease, ISSN 2221-6189, 07/2018, Volume 7, Issue 4, p. 158
Journal Article
PLOS ONE, ISSN 1932-6203, 06/2016, Volume 11, Issue 6
Previous in vivo studies have suggested that nucleic acid polymers (NAPs) may reduce circulating levels of HBsAg in the blood by blocking its release from... 
LAMIVUDINE | ENTECAVIR | THERAPY | VIRUS SURFACE-ANTIGEN | ADEFOVIR DIPIVOXIL | MULTIDISCIPLINARY SCIENCES | PROSTATE-CANCER | IN-VIVO | IMMUNE GLOBULIN | ANTISENSE OLIGONUCLEOTIDE | NATURAL-HISTORY
Journal Article
LIVER TRANSPLANTATION, ISSN 1527-6465, 03/2013, Volume 19, Issue 3, pp. 268 - 274
Without effective prophylaxis, liver transplantation for hepatitis B virus (HBV)related liver disease is frequently complicated by severe and rapidly... 
SURGERY | TENOFOVIR DISOPROXIL FUMARATE | CIRRHOSIS | HBIG | DIPIVOXIL | GASTROENTEROLOGY & HEPATOLOGY | PLUS | TRANSPLANTATION
Journal Article
世界胃肠病学杂志:英文版, ISSN 1007-9327, 2015, Volume 21, Issue 7, pp. 2116 - 2123
AIM:To investigate the predictors of proximal kidney tubular dysfunction(PKTD)induced by adefovir dipivoxil(ADV)treatment for chronic hepatitis... 
dipivoxil;Proximal | kidney | Adefovir | tubular | dysfunc | Adefovir dipivoxil | Hepatitis B virus | Fanconi syndrome | Proximal kidney tubular dysfunction | OSTEOMALACIA | LAMIVUDINE TREATMENT | CONTROLLED-TRIAL | VIRUS-INFECTION | SAFETY | ANTIRETROVIRAL THERAPY | LIVER-DISEASE | FANCONIS-SYNDROME | DIPIVOXIL THERAPY | JAPANESE PATIENTS | GASTROENTEROLOGY & HEPATOLOGY | Kidney Diseases - physiopathology | Japan - epidemiology | Prevalence | Age Factors | Humans | Kidney Diseases - diagnosis | Middle Aged | Male | Hepatitis B, Chronic - diagnosis | Kidney Diseases - genetics | Osteomalacia - chemically induced | Adenine - adverse effects | Time Factors | Kidney Diseases - epidemiology | Kidney Diseases - chemically induced | Aged, 80 and over | Adult | Female | Multidrug Resistance-Associated Proteins - genetics | Retrospective Studies | Odds Ratio | Kidney Tubules, Proximal - physiopathology | Genetic Predisposition to Disease | Adenine - analogs & derivatives | Osteomalacia - epidemiology | Hepatitis B, Chronic - epidemiology | Risk Factors | Organophosphonates - adverse effects | Logistic Models | Organic Anion Transport Protein 1 - genetics | Chi-Square Distribution | Hepatitis B, Chronic - drug therapy | Antiviral Agents - adverse effects | Aged | Polymorphism, Single Nucleotide | Kidney Tubules, Proximal - drug effects | Retrospective Study
Journal Article
NEW ENGLAND JOURNAL OF MEDICINE, ISSN 0028-4793, 04/2006, Volume 354, Issue 17, pp. 1807 - 1812
The reverse-transcriptase inhibitor lamivudine ( Zeffix, GlaxoSmithKline) is often treat chronic infection with hepatitis B virus ( HBV) until resistance... 
LAMIVUDINE | MEDICINE, GENERAL & INTERNAL | TENOFOVIR DISOPROXIL FUMARATE | THERAPY | REPLICATION | HIV | SUSCEPTIBILITY | POLYMERASE | INFECTION | MUTATIONS | DIPIVOXIL
Journal Article
Gastroenterology, ISSN 0016-5085, 2015, Volume 149, Issue 3, pp. 649 - 659
Background & Aims There are no effective and safe treatments for chronic hepatitis C virus (HCV) infection of patients who have advanced liver disease. Methods... 
Gastroenterology and Hepatology | Liver Transplantation | Decompensated Cirrhosis | Hepatitis C Virus Infection | Fibrosing Cholestatic Hepatitis | C INFECTION | TRANSPLANTATION PATIENTS | RECIPIENTS | INTERFERON | THERAPY | ADEFOVIR DIPIVOXIL | CIRRHOSIS | GENOTYPE 1 INFECTION | OUTCOMES | GASTROENTEROLOGY & HEPATOLOGY | United States | Humans | Middle Aged | Fluorenes - therapeutic use | Liver Cirrhosis - mortality | Hepacivirus - genetics | Male | Cholestasis, Intrahepatic - drug therapy | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - mortality | Time Factors | Female | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Benzimidazoles - adverse effects | Drug Therapy, Combination | Cholestasis, Intrahepatic - virology | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Hepacivirus - drug effects | Liver Cirrhosis - drug therapy | Liver Cirrhosis - diagnosis | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - diagnosis | Hepatitis C, Chronic - drug therapy | Disease Progression | Cholestasis, Intrahepatic - mortality | Hepacivirus - enzymology | Liver Cirrhosis - virology | Cholestasis, Intrahepatic - diagnosis | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Drug Combinations | Care and treatment | Liver diseases | Hepatitis C virus | Hepatitis C | Health aspects
Journal Article
Molecular Therapy - Nucleic Acids, ISSN 2162-2531, 01/2014, Volume 3, Issue 8, pp. e186 - e186
Persistence of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) under current antiviral therapy is a major barrier to eradication of chronic... 
MEDICINE, RESEARCH & EXPERIMENTAL | CLOSED CIRCULAR DNA | BACTERIA | HEPATITIS-B-VIRUS | ENDONUCLEASE | HUMAN-CELLS | ADEFOVIR DIPIVOXIL THERAPY | EFFECTOR NUCLEASES | CAS SYSTEMS | INFECTION | ZINC-FINGER NUCLEASES | Original
Journal Article